Gwyn Morgan: Sensible greens would back natural gas.Opinion: Will this episode of inflation have a happy ending?.Terence Corcoran: Canada joins the long march with Xi to global statism.This advertisement has not loaded yet, but your article continues below. With confidential rebates, regulating list prices is less useful. In 1987, when the PMPRB was established, secret rebates were uncommon: drug plans paid list prices. When regulating Canadian list prices for many new patented drugs, the PMPRB relies on the median of the public list prices charged for the same drug in a group of seven comparator countries. The use of secret rebates has also reduced the effectiveness of the PMPRB’s toolbox. Thus countries differ in their contributions towards global drug R&D costs. ![]() There is limited information on actual country-specific prices, but it seems clear that the United States and Canada pay more than countries with national drug plans like the United Kingdom and Australia. To maintain the secrecy, drug companies post public list prices but then give drug plans “off-invoice” rebates that reduce transactions prices. One hallmark of negotiations in many countries is that the prices drug plans pay are kept secret.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |